Evaluation of the in vitro activity of caspofungin against bloodstream isolates of Candida species from cancer patients: comparison of Etest and NCCLS reference methods

The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance

M. Hong Nguyen, James E. Peacock, Arthur J. Morris et al. · The American Journal of Medicine · 1996 · 761 citations

Life Sciences, Infectious Diseases, Microbiology +14

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

K Bartizal, Christopher Gill, George K. Abruzzo et al. · Antimicrobial Agents and Chemotherapy · 1997 · 312 citations · Full text

Life Sciences, Microbiology, Pharmacology +14

In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi

Shuichi Tawara, Fumiaki Ikeda, Katsuyuki Maki et al. · Antimicrobial Agents and Chemotherapy · 2000 · 311 citations

Life Sciences, Microbiology, Pharmacology +17

Activity of MK-0991 (l-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.

Francesc Marco, Michael A. Pfaller, S. A. Messer et al. · Diagnostic Microbiology and Infectious Disease · 1998 · 108 citations

Life Sciences, Microbiology, Pharmacology +11

Evaluation of Etest Method for Determining Caspofungin (MK-0991) Susceptibilities of 726 Clinical Isolates of <i>Candida</i> Species

Michael A. Pfaller, S. A. Messer, K. Mills et al. · Journal of Clinical Microbiology · 2001 · 64 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14